Actively Recruiting
Study of Adebrelimab with Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for First Treatment of Metastatic Pancreatic Cancer
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2024-06-28
20
Participants Needed
1
Research Sites
74 weeks
Total Duration
AI-Summary
What This Trial Is About
Metastatic pancreatic cancer is a highly malignant tumor with a poor outlook. Current immunotherapy combined with chemotherapy shows limited overall effectiveness. This trial explores whether adding decitabine, an epigenetic inhibitor, can improve immunotherapy by enhancing tumor antigen presentation, altering the tumor environment, and boosting immune responses. The study focuses on evaluating the combination of adebrelimab with decitabine, albumin-bound paclitaxel, and gemcitabine as a first treatment for this cancer type. Participants receive a treatment cycle every 28 days including decitabine given by continuous infusion over 1 hour on days 1 to 3, albumin-bound paclitaxel at 125 mgm2 infused intravenously on days 1, 8, and 15, and gemcitabine at 1000 mgm2 intravenously on the same days. Adebrelimab is administered at 1200 mg by IV infusion on day 15 every 3 weeks. Dose adjustments for paclitaxel and gemcitabine may be made if treatment-related side effects occur. During the study, researchers monitor dose limiting toxicities, the recommended dose for phase 2, and the objective response rate for up to 12 months. Secondary measures include overall survival up to 2 years, progression-free survival up to 6 months, disease control rate, duration of response, and safety events. Participants undergo regular assessments to evaluate treatment effects and safety over the study period ending in November 2026.
CONDITIONS
Brief Title
Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here